Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | AGPAT2 | O15120 | 3/20 | 0.44 |
| ▸ | FBP1 | P09467 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6496889 | 0.89 | EPHB4 (0.49) | EPHB4KDM4ENFKB1MAPTMEN1 | |
| SCHEMBL4941396 | 0.83 | EPHB4 (0.64) | EPHB4MAPTMEN1LMNAKMT2A | |
| SCHEMBL6495796 | 0.81 | EPHB4 (0.55) | EPHB4MAPTMEN1LMNAKMT2A | |
| SCHEMBL6481335 | 0.81 | EPHB4 (0.55) | EPHB4MAPTMEN1LMNAKMT2A | |
| SCHEMBL16343865 | 0.73 | RAB9A (0.64) | KDM4EMAPTMEN1LMNAKMT2A | |
| SCHEMBL4836897 | 0.73 | MAPT (0.74) | EPHB4KDM4ENFKB1MAPTMEN1 | |
| SCHEMBL17631140 | 0.73 | EPHB4 (0.52) | EPHB4IGF1R | |
| SCHEMBL4946510 | 0.72 | EPHB4 (0.69) | EPHB4IGF1REGFR | |
| SCHEMBL6483193 | 0.72 | KDR (0.57) | EPHB4MAPTEGFR | |
| SCHEMBL17630793 | 0.72 | MAPK8 (0.53) | EPHB4IGF1REGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6881737-B2 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. (US) | 2005-04-19 | — | — | US | disclosed |
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | AMGEN INC. | 2003-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139416-A1 | Substituted triazinyl acrylamide derivatives and methods of use | PKD1, PKD2, GLS | EPHB4 3547/4885KDM4E 3334/4885NFKB1 1550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.